NASDAQ$EPIX
Essa Pharma Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results for the fiscal second quarter.
ESSA Pharma reported its financial results for the second quarter of fiscal year 2024, highlighting progress in masofaniten combination studies and ongoing clinical development programs. The company's cash runway is expected to fund operations beyond 2025.
- Masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation.
- 81% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL.
- Phase 2 dose expansion is underway, evaluating masofaniten plus enzalutamide in patients with mCRPC.
- Enrollment in Phase 2 is projected to complete in 1Q25, with preliminary data expected in mid-2025.
Headline financials
Revenue & EPS history
Essa Pharma · Revenue · Quarterly
$0
Forward guidance
ESSA Pharma is focused on advancing its clinical programs and expects to report updated data from its studies. The company anticipates completing enrollment in the Phase 2 dose expansion study in the first quarter of 2025, with preliminary data expected in mid-2025.
Tailwinds
- Plans to report updated data from its studies.
- Advancement and evaluation of masofaniten.
- Timing of the Company’s studies.
- Enrollment in the Company’s studies.
- Cash runway sufficient to fund operations beyond 2025
Headwinds
- Risks related to obtaining positive results of clinical trials.
- Risks related to obtaining necessary regulatory approvals.
- General business, market and economic conditions.
- Uncertainties related to medical, scientific, business, economic, competitive, political and social factors.
- The company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q2 2024
-0.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
-3.2%
Avg return
30 days after
39%
13 / 33 earnings
Positive
+46.0%
Q1 2021
Best reaction
-34.9%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.0% | +0.0% | -89.5% | |
| Q2 2025 | +1.2% | -1.8% | -1.2% | |
| Q1 2025 | -3.0% | +3.6% | -2.4% | |
| Q4 2024 | -1.2% | -1.8% | +7.4% | |
| Q3 2024 | -5.5% | -2.6% | +22.9% | |
| Q2 2024 | +4.6% | +4.9% | -21.3% | |
| Q1 2024 | +2.5% | -5.4% | -10.0% | |
| Q4 2023 | +3.2% | +16.4% | +58.7% | |
| Q3 2023 | -2.8% | -4.5% | -5.6% | |
| Q2 2023 | -4.1% | +2.7% | +8.6% | |
| Q1 2023 | +2.1% | +0.3% | -2.4% | |
| Q4 2022 | -6.9% | — | — | |
| Q3 2022 | +3.1% | — | — | |
| Q2 2022 | +5.4% | — | — | |
| Q1 2022 | +1.4% | — | — | |
| Q4 2021 | +0.6% | — | — | |
| Q3 2021 | -34.9% | — | — | |
| Q2 2021 | -1.8% | — | — | |
| Q1 2021 | +46.0% | — | — | |
| Q4 2020 | +8.6% | — | — | |
| Q1 2020 | +0.0% | — | — | |
| Q4 2019 | -0.2% | — | — | |
| Q1 2019 | +3.2% | — | — | |
| Q2 2019 | -8.7% | — | — | |
| Q4 2018 | -2.4% | — | — | |
| Q1 2018 | -8.1% | — | — | |
| Q4 2016 | +0.0% | — | — | |
| Q3 2016 | +0.0% | — | — | |
| Q2 2016 | -5.8% | — | — | |
| Q1 2016 | +2.2% | — | — | |
| Q4 2015 | -8.2% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro